Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck KGaA to keep OTC

This article was originally published in The Tan Sheet

Executive Summary

The German firm maintains a positive outlook for its consumer health business and says it does not plan to sell - contrary to analysts' suggestion Sanofi-Aventis could buy it (1"The Tan Sheet," Jan. 12, 2009, p. 14). "If some braver companies are coming in, yes, that will increase the competition - the consumer will have more choice - but they cannot overtake our brands in two years," pharmaceutical head Elmar Schnee said during the firm's earnings call Feb. 18. Fiscal 2008 OTC revenues grew 5.2 percent to 442 million euros ($599.3 million under same-day conversion rates), and rose 3.7 percent to $144.7 million in the fourth quarter. The U.K.'s depreciating currency value hit the firm's sales

You may also be interested in...

Merck KGaA Consumer Business Could Flourish In The Right Hands – Analysts

Merck KGaA's weak consumer health business could be an acquisition target for a larger, more geographically diverse and innovative firm, such as Sanofi-Aventis, according to an analysts' report

COVID-19 Lockdown: India Pharma Manufacturing Limps Along Amid Challenges

Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts